Cargando…
De Novo Self-Assembling Peptides Mediate the Conversion of Temozolomide and Delivery of a Model Drug into Glioblastoma Multiforme Cells
Glioblastoma multiforme (GBM) is the most aggressive central nervous system tumor, and standard treatment, including surgical resection, radiation, and chemotherapy, has not significantly improved patient outcomes over the last 20 years. Temozolomide (TMZ), the prodrug most commonly used to treat GB...
Autores principales: | Pitz, Megan, Elpers, Margaret, Nukovic, Alexandra, Wilde, Sarah, Gregory, Arica Jordan, Alexander-Bryant, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9495814/ https://www.ncbi.nlm.nih.gov/pubmed/36140265 http://dx.doi.org/10.3390/biomedicines10092164 |
Ejemplares similares
-
Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016) -
Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice
por: van Genugten, J. A. B., et al.
Publicado: (2009) -
Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems
por: Toren, Amos, et al.
Publicado: (2016) -
Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide
por: Wang, Nan, et al.
Publicado: (2021) -
Interfering with mitochondrial dynamics sensitizes glioblastoma multiforme to temozolomide chemotherapy
por: Wang, Nan, et al.
Publicado: (2021)